What is Human insulin?
Human insulin replaces or supplements insulin activity in diabetes. Different formulations have different onset and duration, making product identity especially important.
Biological role or research focus
Blood-glucose regulation.
Different insulin products have different time courses and are not interchangeable by name alone.
Role reference: MedlinePlus · Human insulin ↗
Names you may encounter
insulin
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Glucose-regulating hormone
- Main research area
- Diabetes management
- Evidence featured
- Human randomized trial
- Source check
- October 4, 2026
Source: MedlinePlus · Human insulin ↗
Quick answers
- Is Human insulin FDA approved?
- Yes. Human insulin products including Humulin R/N (BLA 018780, 018781), Novolin R/N (some sold over the counter), Myxredlin and Afrezza inhaled insulin (BLA 022472) for glycemic control in diabetes. Source ↗
- Is Human insulin safe?
- Essential approved hormone for diabetes; the main danger is low blood sugar, which can be severe or fatal, along with low potassium and allergic reactions. Human safety data: its FDA label lists the known risks. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Human insulin banned in sport?
- Yes. The 2026 World Anti-Doping Agency (WADA) Prohibited List names it (S4.4.2 Insulins and insulin-mimetics). Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| DCCT (1993) | Human randomized trial | 1,441 people with type 1 diabetes, with or without early retinopathy. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized trial · 1993
DCCT
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.
- Population / model
- 1,441 people with type 1 diabetes, with or without early retinopathy.
- Study design
- Intensive versus conventional diabetes treatment; average follow-up 6.5 years.
- Main finding
- Intensive management reduced development of retinopathy by 76% in the primary-prevention group and slowed progression by 54% in the other group. Severe hypoglycemia was more frequent.
- Limits & context
- This tested a treatment strategy including monitoring, not one modern brand versus another. It demonstrates the tradeoff between complication reduction and hypoglycemia risk.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
48 registered studies name Human insulin as an intervention among the 100 most recently updated of 8258 search results; 21 are recruiting or under way, 13 have not started recruiting yet, 12 completed and 2 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 48 listed studies.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Downstream processing of recombinant human insulin and its analogues production from E. coli inclusion bodies. ↗
Bioresources and bioprocessing · 2021 · Journal Article, Review
Read available full text ↗
Human insulin. ↗
British medical journal (Clinical research ed.) · 1986 Jan 18 · Editorial
Read available full text ↗
Expression in Escherichia coli of chemically synthesized genes for human insulin. ↗
Proceedings of the National Academy of Sciences of the United States of America · 1979 Jan · Journal Article
Read available full text ↗
Human insulin. ↗
BMJ (Clinical research ed.) · 1989 Oct 21 · Journal Article, Review
Read available full text ↗
Risks & interactions
Essential approved hormone for diabetes; the main danger is low blood sugar, which can be severe or fatal, along with low potassium and allergic reactions.
This entry follows the label for a concentrated human insulin product (Humulin R U-500); the core risks shown apply to insulins in general. Insulin's safety profile is well established through long clinical use.
Take extra care with: Heart or blood pressure problemsDiabetes or blood-sugar medicines
From the FDA label lists below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.
Who should not use it
- During an episode of low blood sugar
- People allergic to the insulin product or any ingredient
Interactions
- Other diabetes drugs, ACE inhibitors, ARBs, fluoxetine, MAO inhibitors, salicylates or sulfa antibiotics: higher low blood sugar risk
- Steroids, diuretics, estrogens, birth control pills, thyroid hormones or atypical antipsychotics: can weaken insulin's effect
- Alcohol, beta-blockers, clonidine or lithium: may raise or lower blood sugar
- Beta-blockers, clonidine, guanethidine or reserpine: can hide warning signs of low blood sugar
- Thiazolidinedione diabetes drugs: fluid retention and heart failure risk
Serious risks
- Severe low blood sugar causing seizures, loss of consciousness or death
- Blood sugar swings when switching insulin products or regimens
- Severe whole-body allergic reactions, including anaphylaxis
- Low blood potassium, which can be life-threatening
- Heart failure when combined with thiazolidinediones
- Infection risk if pens are shared, even with a new needle
Common side effects
- low blood sugar
- allergic reactions
- injection-site reactions
- fat tissue changes at injection sites (lipodystrophy)
- itching
- rash
Summarized from the FDA label with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: DailyMed: Humulin R U-500 (insulin human) prescribing information ↗
Key precautions
Hypoglycemia can be severe or life-threatening. Product, concentration, timing, meals, illness, and activity affect risk. This page is a research reference and does not calculate or recommend insulin doses.
Source: MedlinePlus · Human insulin ↗
Regulatory status
- U.S. FDA approval
- Approved
Human insulin products including Humulin R/N (BLA 018780, 018781), Novolin R/N (some sold over the counter), Myxredlin and Afrezza inhaled insulin (BLA 022472) for glycemic control in diabetes. source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not on FDA's 503A nominated-substance category lists. As a component of an FDA-approved drug it does not need to be on the 503A bulks list to be used in pharmacy compounding (other 503A conditions still apply). source - World Anti-Doping Agency (2026)
- Prohibited, named on the list · S4.4.2 Insulins and insulin-mimetics
Insulins are named as a prohibited class at all times; a Therapeutic Use Exemption is required for medical use. source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Clinical uses & product context
It is central to type 1 diabetes care and used in selected people with type 2 diabetes. DCCT examined the benefits and risks of an intensive management strategy, including frequent monitoring.
Source: MedlinePlus · Human insulin ↗
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
This is a prescription medicine, available only with a prescription through a pharmacy. Versions sold online as "research" products are not the approved medicine, and the FDA has warned sellers of them, so PepsRadar does not list, compare or link them. See the official product information linked in References.
Mechanism & research rationale
Insulin helps tissues take up glucose and reduces the liver’s glucose output. Formulation changes alter the time course of that activity.
Source: MedlinePlus · Human insulin ↗
Molecular structure
Questions worth asking
- Which indication and formulation does the source describe?
- Does the video make a broader claim than the source supports?
- Different insulin products have different time courses and are not interchangeable by name alone.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Video & podcast discussions: members library
Frequently asked questions
Is every insulin product interchangeable?
No. Time-action profiles and concentrations differ; substitution requires the correct clinical instructions.
Source: MedlinePlus · Human insulin ↗
Did DCCT identify one best insulin brand?
No. It compared management strategies, not all modern products head to head.
References & editorial record
- MedlinePlus · Human insulin ↗
- The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. ↗
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
